Syncom Formulations (India) Ltd

Syncom Formulations (India) Limited announced changes to its board and senior management, effective August 11, 2026. The company said Kedarmal Shankarlal Bankda and Vijay Shankarlal Bankda resigned from their respective positions as Whole-time Director and Managing Director, while Rahul Vijay Bankda resigned as Chief Financial Officer. Subsequently, Rinki Ankit Bankda was appointed as Additional Director and Whole Time Director, Rahul Vijay Bankda as Additional Director and Managing Director, and Ankur Vijay Bankda as Chief Financial Officer, all subject to shareholder approval at the upcoming Annual General Meeting. Additionally, Smt. Ruchi Jindal was reappointed as Woman Independent Director, effective June 29, 2027, also pending shareholder approval.

Syncom Formulations (India) Limited has fixed Wednesday, September 23, 2026, as the record date for determining entitlement to a dividend of Rs. 0.10 per equity share, representing 10% for the financial year ended March 31, 2026, subject to shareholder approval at the company’s 38th Annual General Meeting to be held on Wednesday, September 30, 2026, at 2:00 P.M. via video conferencing or other audio-visual means.

SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.

SYNCOM Formulations (India) Limited will hold a board meeting on Tuesday, August 11, 2026, at 4:00 P.M. (IST) to consider and approve the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026, and to take on record the limited review report by auditors, as well as to consider a final dividend recommendation for the financial year ended March 31, 2026.

Net profit of Syncom Formulations (India) rose 42.28% to Rs 25.17 crore in the quarter ended March 2026 as against Rs 17.69 crore during the previous quarter ended March 2025. Sales declined 9.05% to Rs 135.41 crore in the quarter ended March 2026 as against Rs 148.88 crore during the previous quarter ended March 2025. For the full year,net profit rose 54.64% to Rs 76.44 crore in the year ended March 2026 as against Rs 49.43 crore during the previous year ended March 2025. Sales rose 5.20% to Rs 489.17 crore in the year ended March 2026 as against Rs 465.01 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales135.41148.88 -9 489.17465.01 5 OPM %16.2511.92 -15.8311.64 - PBDT36.1824.58 47 107.6170.70 52 PBT33.7023.29 45 101.0865.50 54 NP25.1717.69 42 76.4449.43 55 Powered by Capital Market - Live

Net profit of Syncom Formulations (India) rose 40.40% to Rs 24.57 crore in the quarter ended March 2026 as against Rs 17.50 crore during the previous quarter ended March 2025. Sales declined 9.74% to Rs 134.00 crore in the quarter ended March 2026 as against Rs 148.46 crore during the previous quarter ended March 2025. For the full year,net profit rose 55.54% to Rs 76.01 crore in the year ended March 2026 as against Rs 48.87 crore during the previous year ended March 2025. Sales rose 5.12% to Rs 486.57 crore in the year ended March 2026 as against Rs 462.85 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales134.00148.46 -10 486.57462.85 5 OPM %16.0311.77 -15.8611.56 - PBDT35.3424.28 46 107.0169.83 53 PBT32.8622.99 43 100.4864.64 55 NP24.5717.50 40 76.0148.87 56 Powered by Capital Market - Live

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 22 May 2026.

Net profit of Syncom Formulations (India) rose 45.46% to Rs 18.91 crore in the quarter ended December 2025 as against Rs 13.00 crore during the previous quarter ended December 2024. Sales declined 9.72% to Rs 115.14 crore in the quarter ended December 2025 as against Rs 127.53 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales115.14127.53 -10 OPM %18.4211.55 - PBDT26.4518.57 42 PBT25.0917.26 45 NP18.9113.00 45 Powered by Capital Market - Live

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 12 February 2026.Powered by Capital Market - Live

Net profit of Syncom Formulations (India) rose 49.41% to Rs 16.60 crore in the quarter ended September 2025 as against Rs 11.11 crore during the previous quarter ended September 2024. Sales rose 18.97% to Rs 121.72 crore in the quarter ended September 2025 as against Rs 102.31 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales121.72102.31 19 OPM %15.1211.89 - PBDT23.3916.15 45 PBT22.0414.85 48 NP16.6011.11 49 Powered by Capital Market - Live